Edaravone reduces depression severity in patients with symptomatic intracranial stenosis and is associated with the serum expression of sex hormones

Abstract

Objective: To investigate the effect of edaravone on depression relief in symptomatic patients with intracranial stenosis and its relationship with the expression of sex hormones. Methods: We recruited 112 patients with symptomatic intracranial arterial stenosis from Renmin Hospital, Wuhan University, between October 2014 and October 2017. All patients were divided into the traditional or experimental (traditional treatment + intravenous infusion of edaravone 30 mg twice a day for 14 days) treatment groups. The general clinical data were collected, and neurological functional recovery using the Modified Rankin Scale (mRS) and National Institute of Health stroke scale (NIHSS) scores were recorded. Symptom Checklist 90 (SCL-90) was used to assess the general psychological changes of the patient, followed by the 24 Hamilton Depression Scale (HAMD) to examine the incidence of post-stroke depression (PSD). This divided the patients into the mild, moderate, and severe depression groups. Next, we measured the serum protein expression of the sex hormones estradiol (E2), testosterone (T), follicle stimulating hormone (FSH), prolactin (PRL), and luteinizing hormone (LH). Results: The mRS and NIHSS scores were significantly lower in the experimental group than in the control group (P < .05). There was no significant difference in SCL90 score before intervention (P > .05); the scores were significantly lower in the experimental group after intervention (P < .05). There was a significant difference in SCL-90 and HAMD scores between groups before treatment (P < .05), with significantly lower scores in the experimental group post-treatment (P < .05). The incidence of depression was significantly reduced in the experimental group post-treatment. Furthermore, the expression of E2 and FSH was significantly higher (P < .01) and lower (P < .001), respectively, in women than in men in the experimental group post-treatment. Interestingly, the expression of T was significantly lower in men in the experimental group post-treatment (P < .001). Conclusion: Edaravone significantly improved the clinical efficacy of stent implantation in intracranial artery stenosis treatment by alleviating depression and reducing the incidence of PSD.

Evaluation of the efficacy of aspirin combined with low doses of clopidogrel in the treatment of symptomatic intracranial artery stenosis in the elderly

“…The treatment of symptomatic ICAS, which seriously affects patients' quality of life and increases the socioeconomic burden, is a hot topic of clinical research, but the choice between pharmacological and PTA treatment modalities has been controversial. Studies have shown that PTA can partially restore neurological function and reduce mortality in patients with symptomatic ICAS [11] , but complications related to ischemia-reperfusion, embolic dislodgement, and bleeding can increase stroke recurrence and mortality, seriously affecting the clinical prognosis of patients [12] . Some studies also suggested that aggressive pharmacological interventions are preferable to PTA [13] .…”

Neurocognitive improvement after angioplasty in patients with chronic middle cerebral artery stenosis and cerebral ischemia

“…Nearly no literature exists concerning the neurocognitive function of patients with middle cerebral artery stenosis (MCAS) and objective cerebral ischemia. Our previous study therefore investigated the protective effect of edaravone on symptomatic intracranial artery stenosis after stent implantation and its relationship with sex hormones (10). The aim of the present study was to evaluate the cognitive function changes in chronic MCAS patients accepted before and after MCA angioplasty and to explore the influence of MCAS and objective cerebral ischemia.…”

Edaravone Improved Behavioral Abnormalities, Alleviated Oxidative Stress Inflammation, and Metabolic Homeostasis Pathways in Depression

“…The main underling mechanism consists of antiapoptotic properties of this substance would have a boosting effect on BCL-2 expression by demonstrating mitochondrial functional recovery, which is achieved by ATP production modulation and inhibiting mitochondrial swelling during accumulation of reactive oxygen species in neural cell [15,16]. EDV can modulate HPA-axis function and gene pathways related to depression [17,18].…”